Recent News About Pfizer
-
Pharmaceutical makers have paid $242 million to Illinois to end litigation over drug prices, which dates to 2005.
-
A federal judge has again rejected pharmaceutical maker Pfizer’s request to end a potential consumer fraud class action over the labeling of its Robitussin Maximum Strength cough and cold medicine.
-
A federal judge has rejected Pfizer’s attempt to scuttle a class action accusing the drugmaker of misleading consumers over the actual strength of its maximum strength Robitussin cough syrup, saying a U.S. Supreme Court decision doesn’t necessarily mean the company shouldn’t have to face a nationwide class action in Chicago federal court.
